DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key pulmonary hypertension patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download. Use the extended worldwide coverage data set to:

  • View 10-year forecasts of the first-line drug-treatable population and diagnosed incident cases for all 171 countries, stratified by region and World Bank income status.
  • Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
  • Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
  • Generate and export global heat maps of disease risk or patient population size.

The extended worldwide coverage dashboard is available as an Excel file in the “Downloads” section. It is available only to clients with subscriptions to all 45 countries covered by DRG Epidemiology. For subscription and entitlement queries, please contact questions@teamdrg.com.

Table of contents

  • Extrapolated Worldwide Coverage
    • Extrapolated Worldwide Coverage
      • Introduction
      • Download
      • The Global Extrapolator Model
      • The Global Extrapolation Algorithm

Author(s): Alison Isherwood, MSc, MRes, PhD

Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.


Related Reports

Pulmonary Hypertension | Landscape & Forecast | Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the p...

View Details

Hypertension | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., co...

View Details

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis (US)

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the tr...

View Details

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Pulmonary Arterial Hypertension (US)

MARKET OUTLOOK Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. A wide array of drugs are available for PAH...

View Details